Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap

Impact · against what's priced in

The news is largely neutral for Incyte as the current price already assumes modest growth and stability in its core portfolio. While clinical data for KRAS G12D and TGFβR2×PD-1 provides a positive signal, the market continues to discount the full upside of a post-Jakafi diversification strategy.

INCY+0.00

Already priced in

The price assumes

Opzelura's current $0.68bn in sales and its immediate near-term trajectory

Increased guidance for Opzelura and 14% YoY Q3 sales growth align with the market's current assumption of steady near-term growth for the non-Jakafi portfolio.

What INCY's price assumes · Sep 22

• clinical trials▲8%
• earnings
• guidance
• pharmaceuticals
• biotech
• INCY
• oncology
• stock upgrade

Top 1 mover · tap to explore